- Home
- MRNA vs RPRX Comparison
MRNA vs RPRX Comparison
Compare MRNA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | RPRX |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.5B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRNA | RPRX |
|---|---|---|
| Price | $50.59 | $49.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $34.27 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 5.2M | 2.5M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | ★ $19,263,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $9.36 | $38.63 |
| Revenue Next Year | $15.43 | $4.73 |
| P/E Ratio | ★ N/A | $27.85 |
| Revenue Growth | 4.29 | ★ 5.06 |
| 52 Week Low | $22.28 | $31.97 |
| 52 Week High | $59.55 | $50.08 |
Technical Indicators
Market Signals| Indicator | MRNA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 60.46 |
| Support Level | $47.61 | $35.34 |
| Resistance Level | $54.94 | N/A |
| Average True Range (ATR) | 2.64 | 0.88 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 37.52 | 77.82 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.